ErdoganA, OzcayF, PiskinE, KaramanMG, BilezikciB, CalikM, HaberalM: Idiosyncratic liver failure probably associated with atomoxetine: A case report. J Child Adolesc Psychopharmacol, 21:295–297, 2011.
2.
LimJR, FaughtPR, ChalasaniNP, MollestonJP: Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr, 148:831–834, 2006.
3.
MerikangasKR, HeJP, BrodyD, FisherPW, BourdonK, KoretzDS: Prevalence and treatment of mental disorders among US children in the 2001–2004 NHANES. Pediatrics, 125:75–81, 2010.
4.
SchwartzS, CorrellCU: Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: Results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry, 53:174–187, 2014.
5.
WolraichML, HaganJF, AllanC, ChanE, DavisonD, EarlsM, EvansSW, FlinnSK, FroehlichT, FrostJ, HolbrookJR: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics, 144:e20192528, 2019.
